Boehringer Ingelheim Scientist III, Molecular Pathology in RIDGEFIELD, Connecticut

Boehringer Ingelheim is an equal opportunity global employer who takes pride in maintaining a diverse and inclusive culture. We embrace diversity of perspectives and strive for an inclusive environment which benefits our employees, patients and communities.

The Experimental Pathology group at Boehringer Ingelheim is currently seeking several talented Scientists for a new Molecular Pathology lab within Non-clinical Drug Safety for Development at the Ridgefield, CT, site. Our team uses state-of-the-art tissue-based methods to support drug safety evaluation. By integrating histopathology with current molecular and imaging techniques. This lab will provides novel biomarkers and enhanced biological context for safety decisions.

Description:

Oversight of methods development for all tissue based molecular endpoints (immunohistochemistry (IHC), in situ hybridization (ISH), laser capture microdissection (LCM), etc.). Primary responsibility for initiation and oversight of methods development for project required tissue cross reactivity (TCR)/TTP studies (includes scheduling, securing needed reagents, etc.); support for methods transfer for GLP studies (e.g., reagent shipments). Writes protocols, methods and technical reports.

As an employee of Boehringer Ingelheim, you will actively contribute to the discovery, development and delivery of our products to our patients and customers. Our global presence provides opportunity for all employees to collaborate internationally, offering visibility and opportunity to directly contribute to the companies' success. We realize that our strength and competitive advantage lie with our people. We support our employees in a number of ways to foster a healthy working environment, meaningful work, diversity and inclusion, mobility, networking and work-life balance. Our competitive compensation and benefit programs reflect Boehringer Ingelheim's high regard for our employees

Duties & Responsibilities:

  • Primary responsibility for the oversight and conduct of methods developmentfor needed tissue cross reactivity studies;ensures all needed reagents and control materials are ordered andreceived from Research in a timely fashion, oversees labelling andcharacterization of labelled reagents as needed, supervises technical conductof methods development activities and provides input to ensure methods areoptimized and "fit for purpose", writes method development reportsfor transfer to Contract Research Organization (CRO) for validation accordingto Good Laboratory Practices (GLP). Works independently.

  • Develops, conducts and/or optimizes novel tissue/cell based assays tosupport incorporation of improved safety or mechanistic endpoints into NDSnon-clinical safety evaluations. Proposes new assays, techniques, or approachesbased on current information.

  • Documents all work activities and maintains all assigned study recordsaccurately, completely and in accordance with study protocols by followingapplicable company policies, using current forms and procedures, and making allentries legibly, correctly and contemporaneously.

  • Performs all work safely and in compliance with all applicableregulations, SOPs, company policies, safety training and procedures.

Requirements:

  • One of the following is required:Bachelor’s Degree from an accredited institution with 10+ years of experiencein a relevant scientific discipline; A Master’s Degree from an accreditedinstitution with six-plus (6+) years of experience in a relevant scientificdiscipline

  • Histotechnician (HT)/Histoechnologist (HTL) with Qualification inImmunohistochemistry (QIHC) or eligible with 10+ years’ experience in immunohistochemistryand/or in situ hybridization methods development in a laboratory environment.

  • Hands on experience in assay development and optimization, data analysisand interpretation.

  • Knowledge and experience in the principles and approaches for developmentof Immunohistochemistry (IHC), in situ hybridization (ISH) assays

  • Knowledge and experience in the principles and approaches for developmentof antibody reagent characterization, cataloging

  • Laboratory management experience.

Eligibility Requirements:

  • Must be legally authorized to work in the United States without restriction.

  • Must be willing to take a drug test and post-offer physical (if required)

  • Must be 18 years of age or older

Our Culture:

Boehringer Ingelheim is a different kind of pharmaceutical company, a privately held company with the ability to have an innovative and long term view. Our focus is on scientific discoveries that improve patients' lives and we equate success as a pharmaceutical company with the steady introduction of truly innovative medicines. Boehringer Ingelheim is the largest privately held pharmaceutical corporation in the world and ranks among the world's 20 leading pharmaceutical corporations. At Boehringer Ingelheim, we are committed to delivering value through innovation. Employees are challenged to take initiative and achieve outstanding results. Ultimately, our culture and drive allows us to maintain one of the highest levels of excellence in our industry. Boehringer Ingelheim, including Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim USA, Boehringer Ingelheim Animal Health USA, Inc. and Boehringer Ingelheim Fremont, Inc. is an equal opportunity employer - Minority/Female/Protected Veteran/Person with a Disability

Boehringer Ingelheim is firmly committed to ensuring a safe, healthy, productive and efficient work environment for our employees, partners and customers. As part of that commitment, Boehringer Ingelheim conducts pre-employment verifications and drug screenings.

#LI-SS1

Organization: US-BI Pharma/BI USA

Title: Scientist III, Molecular Pathology

Location: Americas-United States-CT-Ridgefield

Requisition ID: 188362